ALEMBIC PHARMACEUTICALS LTD.

Alembic Pharmaceuticals Limited has executed a Shareholders' Agreement to invest in a newly incorporated Canadian Corporation, 17989377 Canada Inc. The agreement, made with Difgen Holdings LLC and Mr. Sukhad Juneja, aims to establish a platform for developing, commercializing, distributing, and marketing pharmaceutical products in the Canadian market. Alembic Pharmaceuticals will hold a 45% equity stake in the Canadian Corporation, with Difgen Holdings LLC also holding 45% and others holding 10%. The Canadian Corporation will become an associate of Alembic Pharmaceuticals post-investment. The transaction is not considered a related party transaction and is conducted at arm's length.

Alembic Pharmaceuticals Ltd has issued a reminder letter to shareholders holding shares in physical form, urging them to update their Know Your Customer (KYC) details, including PAN, bank account, and nomination information. This action is in compliance with SEBI regulations, which mandate these updates for continued dividend payments and to facilitate electronic credit. Failure to update by April 1, 2024, may result in dividend withholding. The company also encourages shareholders to dematerialize their shares for better liquidity and easier transactions.

Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Haloperidol Tablets, USP, in strengths of 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg. This approval makes the product therapeutically equivalent to the reference listed drug, Haldol Tablets. Haloperidol Tablets are used for managing psychotic disorders and Tourette's Disorder. The estimated market size for these tablets is US$ 27 million. This marks Alembic's 221st final ANDA approval from the USFDA, contributing to their total of 240 approvals.

Alembic Pharmaceuticals Ltd has announced the appointment of Mr. Tushar Mehta as Head-R&D (API), a Senior Management Personnel, effective June 3, 2026. Mr. Mehta brings over 24 years of extensive experience in API R&D, having led numerous development programs and commercializations. His expertise spans complex small-molecule APIs, including oncology and antiviral products. Prior to this role, he held senior R&D positions at Cadila Pharmaceuticals and other leading pharmaceutical companies. This appointment is expected to bolster Alembic's research and development capabilities in the API segment.

Alembic Pharmaceuticals Ltd has announced a change in its Senior Management Personnel. Effective June 2, 2026, Mr. Atul Suri (Senior Vice President - Sales & Marketing) and Mr. Prag Goel (Vice President - Sales & Marketing) will cease to be part of the Senior Management. This change is due to an internal shift in reporting structure, where they will now report to Mr. Ramesh Juneja, Executive Vice President — Human Health (Sales and Marketing), India Business. The company has provided the necessary details as per SEBI regulations.

Alembic Pharmaceuticals Ltd has designated Mr. Ramesh Juneja, Executive Vice President — Human Health (Sales and Marketing) India Business, as Senior Management Personnel, effective June 1, 2026. The company disclosed this appointment in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Juneja's profile includes a pharmacy degree, an MBA, and executive development programs, along with over three decades of experience in pharmaceutical sales and marketing, including leadership roles at Sun Pharmaceutical Industries and Cipla.

Alembic Pharmaceuticals Ltd. has received USFDA final approval for Levothyroxine Sodium Tablets USP in multiple strengths (25 mcg to 300 mcg). The approved ANDA is therapeutically equivalent to AbbVie's Synthroid Tablets. These tablets are used as replacement therapy for hypothyroidism and as an adjunct to surgery and radioiodine therapy for thyroid cancer. The market size for Levothyroxine Sodium Tablets USP is estimated at US$ 1,869 million for the twelve months ending March 2026, according to IQVIA. Alembic now has a total of 239 ANDA approvals from the USFDA.

Alembic Pharmaceuticals Ltd. announces successful completion of the Brazilian Health Regulatory Agency (ANVISA) GMP inspection at its API-III Facility in Karakhadi. The inspection, conducted from May 11, 2026, to May 15, 2026, resulted in clearance for multiple APIs without any observations, indicating adherence to GMP standards.

Alembic Pharmaceuticals Ltd reported its consolidated financial results for Q4 FY26. Revenue from operations increased by 4% YoY to ₹1,848 Cr. Profit After Tax stood at ₹203 Cr, up 29% YoY. EBITDA pre R&D increased by 8% YoY to ₹455 Cr. The company launched its US branded business with Pivya. India Branded Business delivered 4% YoY growth, reaching ₹568 Cr. US Formulation grew by 11% to ₹564 Cr.

Alembic Pharmaceuticals Ltd. announced audited financial results for the quarter and financial year ended March 31, 2026. The Board of Directors approved the standalone and consolidated audited financial results. Revenue from operations for FY26 stood at ₹6,651.38 crore, and profit before tax was ₹608.59 crore. The board also recommended a dividend. The audit report issued by KKC & Associates LLP, Chartered Accountants, has an unmodified opinion on the financial results.